The objective of this quality improvement study was to determine the effect of an institution-wide switch of routine bloodwork from four-week intervals to six-week intervals on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) targets for patients on chronic hemodialysis.
Rationale \& Objective: Routine bloodwork for patients on hemodialysis has both financial and opportunity costs, but there is little data on how the frequency of measurement affects patient outcomes. Our objective was to determine the effect of changing from routine bloodwork at four-week intervals to six-week intervals on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) targets. Study Design: Retrospective interrupted time series from June 1, 2012 to December 31, 2015. Setting \& Participants: Tertiary hospital in Ontario, Canada, that provides hemodialysis to 350-400 adult patients. Quality Improvement Activities: Institution-wide switch of routine bloodwork from four-week intervals to six-week intervals on March 24, 2014. Outcomes: Proportion of patients who achieved recommended hemoglobin and phosphate targets. In a 252-day sub-analysis, we also calculated the cost-savings attributable to a change in laboratory testing frequency for hemoglobin, ferritin, iron saturation, calcium, and phosphate. Analytical Approach: Statistical Process Control to analyze variation in the clinical outcomes.
Study Type
OBSERVATIONAL
Enrollment
400
Routine hemodialysis bloodwork done every 4 weeks
Routine hemodialysis bloodwork done every 6 weeks
Hemoglobin target achievement
Proportion of patients who achieved hemoglobin (10-12 g/dl)
Time frame: 650 days
Phosphate target achievement
Proportion of patients who achieved phosphate (2.5-4.6 mg/dl)
Time frame: 650 days
Use of erythropoietin
Proportion of patients on erythropoietin
Time frame: 650 days
Calcium target achievement
Proportion of patients with calcium (8.8-10.2 mg/dl)
Time frame: 650 days
PTH target achievement
Proportion of patients with PTH (94-462 pg/ml)
Time frame: 650 days
All-cause mortality
All-cause mortality
Time frame: 650 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.